Iplex is a drug owned by Insmed Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 28, 2014. Details of Iplex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5681818 | Therapeutic uses of human somatomedin carrier proteins |
Oct, 2014
(10 years ago) |
Expired
|
FDA has granted several exclusivities to Iplex. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Iplex, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Iplex.
Exclusivity Information
Iplex holds 1 exclusivities. All of its exclusivities have expired in 2012. Details of Iplex's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 12, 2012 |
US patents provide insights into the exclusivity only within the United States, but Iplex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Iplex's family patents as well as insights into ongoing legal events on those patents.
Iplex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Iplex's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 28, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Iplex Generics:
There are no approved generic versions for Iplex as of now.
About Iplex
Iplex is a drug owned by Insmed Inc. It is used for promoting linear growth in the treatment of primary IGF-1 deficiency. Iplex uses Mecasermin Rinfabate Recombinant as an active ingredient. Iplex was launched by Insmed in 2005.
Approval Date:
Iplex was approved by FDA for market use on 12 December, 2005.
Active Ingredient:
Iplex uses Mecasermin Rinfabate Recombinant as the active ingredient. Check out other Drugs and Companies using Mecasermin Rinfabate Recombinant ingredient
Treatment:
Iplex is used for promoting linear growth in the treatment of primary IGF-1 deficiency.
Dosage:
Iplex is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 36MG/0.6ML | INJECTABLE | Discontinued | SUBCUTANEOUS |